Marksans Pharma (MARKSANS) Aktienübersicht
Marksans Pharma Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Herstellung, Vermarktung und dem Verkauf von pharmazeutischen Formulierungen in den Vereinigten Staaten, Nordamerika, Europa, dem Vereinigten Königreich, Australien, Neuseeland und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 3/6 |
| Künftiges Wachstum | 2/6 |
| Vergangene Leistung | 5/6 |
| Finanzielle Gesundheit | 5/6 |
| Dividenden | 3/6 |
Belohnungen
Risikoanalyse
MARKSANS Community Fair Values
Create NarrativeSee what 35 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Marksans Pharma Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹320.85 |
| 52-Wochen-Hoch | ₹345.50 |
| 52-Wochen-Tief | ₹155.00 |
| Beta | 1.12 |
| 1 Monat Veränderung | 23.26% |
| 3 Monate Veränderung | 51.44% |
| 1 Jahr Veränderung | 77.15% |
| 3 Jahre Veränderung | 186.35% |
| 5 Jahre Veränderung | 347.18% |
| Veränderung seit IPO | 1,079.81% |
Aktuelle Nachrichten und Updates
Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited 's ( NSE:MARKSANS ) will be rubbing their hands together with glee today...
MARKSANS: Higher Margin Outlook And Dividend Plans Will Support Upside Potential
The analyst price target for Marksans Pharma has been revised from ₹298 to ₹385, with analysts pointing to updated assumptions for discount rates, revenue growth, profit margins, and future P/E as the key drivers of this change. What’s in the News for Marksans Pharma A board meeting is scheduled on 12 August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.Recent updates
Marksans Pharma Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
The investors in Marksans Pharma Limited 's ( NSE:MARKSANS ) will be rubbing their hands together with glee today...MARKSANS: Higher Margin Outlook And Dividend Plans Will Support Upside Potential
The analyst price target for Marksans Pharma has been revised from ₹298 to ₹385, with analysts pointing to updated assumptions for discount rates, revenue growth, profit margins, and future P/E as the key drivers of this change. What’s in the News for Marksans Pharma A board meeting is scheduled on 12 August 2026 to consider and approve the unaudited standalone and consolidated financial results for the quarter ended 30 June 2026.
MARKSANS: Dividend Decision And Stable Assumptions Will Shape Measured Future Share Rerating
Analysts have kept their Marksans Pharma fair value estimate broadly unchanged at ₹266. This reflects consistent assumptions on discount rate, revenue growth, profit margin, and future P/E in their latest price target update.Unused Capacity And Regulated Market Expansion Will Drive A Stronger Future Margin Profile
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceuticals company focused on generic formulations across regulated markets including the U.S., U.K., Europe, Australia, New Zealand and select other regions. What are the underlying business or industry changes driving this perspective?MARKSANS: Upcoming Dividend Decision Will Support Positive Share Price Rerating
Analysts have lifted the Marksans Pharma price target from ₹216.67 to ₹266.00, citing updated assumptions for revenue growth, profit margins, a slightly lower discount rate, and an adjusted future P/E input. What's in the News A board meeting was held on May 26, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Rising North America Dependence And Overextended Pipeline Will Pressure Margins And Earnings
Catalysts About Marksans Pharma Marksans Pharma is a global pharmaceutical company focused on generic formulations across regulated markets including North America, the U.K., Europe, Australia and New Zealand. What are the underlying business or industry changes driving this perspective?Earnings Beat: Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Marksans Pharma Limited ( NSE:MARKSANS ) defied analyst predictions to release its full-year results, which were ahead...Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...Marksans Pharma Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions
It's been a pretty great week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with its shares surging 13% to...Marksans Pharma Limited's (NSE:MARKSANS) Shares May Have Run Too Fast Too Soon
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 22.2x...Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analysts Have Made A Financial Statement On Marksans Pharma Limited's (NSE:MARKSANS) Second-Quarter Report
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...MARKSANS: Upcoming Board Meeting And UK Regulatory Success Will Drive Momentum
Analysts have reduced their price target for Marksans Pharma from ₹231.67 to ₹216.67. They cite slight increases in the discount rate and a modest drop in the company's projected future price-to-earnings ratio as reasons for the adjustment.Here's Why We Think Marksans Pharma (NSE:MARKSANS) Might Deserve Your Attention Today
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Developed Markets Will Support Affordable Generic Expansion
Marksans Pharma's consensus price target has been revised downward, primarily due to sharply reduced revenue growth forecasts and a decline in net profit margin, lowering the fair value estimate from ₹301.00 to ₹231.67. What's in the News Board re-appointed Mr. Mark Saldanha as Managing Director, subject to shareholder approval at the upcoming AGM.Marksans Pharma Limited (NSE:MARKSANS) Analysts Are Reducing Their Forecasts For This Year
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Marksans Pharma Limited (NSE:MARKSANS) Doing What It Can To Lift Shares
NSEI:MARKSANS 1 Year Share Price vs Fair Value Explore Marksans Pharma's Fair Values from the Community and select...Calculating The Intrinsic Value Of Marksans Pharma Limited (NSE:MARKSANS)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Marksans Pharma fair value estimate is ₹239 With ₹253 share...We Think That There Are Some Issues For Marksans Pharma (NSE:MARKSANS) Beyond Its Promising Earnings
Marksans Pharma Limited's ( NSE:MARKSANS ) robust recent earnings didn't do much to move the stock. However the...₹299: That's What Analysts Think Marksans Pharma Limited (NSE:MARKSANS) Is Worth After Its Latest Results
It's been a good week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, because the company has just released...Should You Be Adding Marksans Pharma (NSE:MARKSANS) To Your Watchlist Today?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Here's Why Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Marksans Pharma Limited's (NSE:MARKSANS) P/E Is On The Mark
It's not a stretch to say that Marksans Pharma Limited's ( NSE:MARKSANS ) price-to-earnings (or "P/E") ratio of 24.6x...Marksans Pharma Limited (NSE:MARKSANS) Just Reported Earnings, And Analysts Cut Their Target Price
It's been a mediocre week for Marksans Pharma Limited ( NSE:MARKSANS ) shareholders, with the stock dropping 15% to...Is Marksans Pharma Limited (NSE:MARKSANS) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Marksans Pharma's estimated fair value is ₹190 based on 2 Stage Free Cash Flow to Equity Marksans Pharma's...
Teva Pharma Facility And US Expansion To Strengthen Future Outlook
Strategic growth in the U.S. market and facility expansion bolster revenue growth, earnings, and profit margins through enhanced capacity and market share.Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 28% As Investors Are Less Pessimistic Than Expected
Despite an already strong run, Marksans Pharma Limited ( NSE:MARKSANS ) shares have been powering on, with a gain of...Is Now The Time To Put Marksans Pharma (NSE:MARKSANS) On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Optimistic Investors Push Marksans Pharma Limited (NSE:MARKSANS) Shares Up 45% But Growth Is Lacking
Marksans Pharma Limited ( NSE:MARKSANS ) shares have continued their recent momentum with a 45% gain in the last month...Marksans Pharma Limited (NSE:MARKSANS) Stock Rockets 26% But Many Are Still Ignoring The Company
Marksans Pharma Limited ( NSE:MARKSANS ) shareholders would be excited to see that the share price has had a great...Solid Earnings May Not Tell The Whole Story For Marksans Pharma (NSE:MARKSANS)
The market shrugged off Marksans Pharma Limited's ( NSE:MARKSANS ) solid earnings report. We did some digging and...Does Marksans Pharma (NSE:MARKSANS) Deserve A Spot On Your Watchlist?
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...Sentiment Still Eluding Marksans Pharma Limited (NSE:MARKSANS)
When close to half the companies in India have price-to-earnings ratios (or "P/E's") above 32x, you may consider...Here's Why Marksans Pharma (NSE:MARKSANS) Has Caught The Eye Of Investors
For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...We Think Marksans Pharma (NSE:MARKSANS) Can Manage Its Debt With Ease
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Aktionärsrenditen
| MARKSANS | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 5.8% | -1.0% | -1.0% |
| 1Y | 77.1% | 15.7% | 1.2% |
Rendite im Vergleich zur Industrie: MARKSANS übertraf die Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 15.7 erzielte.
Rendite vs. Markt: MARKSANS übertraf den Markt Indian, der im vergangenen Jahr eine Rendite von 1.2 erzielte.
Preisvolatilität
| MARKSANS volatility | |
|---|---|
| MARKSANS Average Weekly Movement | 8.1% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 3.6% |
Stabiler Aktienkurs: Der Aktienkurs von MARKSANS war in den letzten 3 Monaten im Vergleich zum Indian -Markt volatil.
Volatilität im Zeitverlauf: MARKSANSDie wöchentliche Volatilität (8%) war im vergangenen Jahr stabil, liegt aber immer noch höher als bei 75 % der Indian Aktien.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1992 | 1,685 | Mark Saldanha | marksanspharma.com |
Marksans Pharma Limited ist zusammen mit seinen Tochtergesellschaften in der Forschung, Herstellung, Vermarktung und dem Verkauf von pharmazeutischen Formulierungen in den Vereinigten Staaten, Nordamerika, Europa, dem Vereinigten Königreich, Australien, Neuseeland und international tätig. Das Unternehmen bietet Produkte in den Bereichen Schmerztherapie, obere Atemwege, Herz-Kreislauf, zentrales Nervensystem, Antidiabetika, Magen-Darm, Analgetika, obere Atemwege, Ohrenpflege, Hautpflege, Anti-Krebs, Anti-Ulkus, Anti-Allergie, antivirale, diätetische, Herz-, Dermatologie, Antihistaminika, Anti-Pilz-, Anti-Virus-, Abführmittel und Erkältung und Husten therapeutischen Bereichen. Das Unternehmen stellt auch eine Reihe fester oraler Darreichungsformen her, darunter Tabletten und Hartgelatinekapseln, Weichgels, ätherische Öle, Salben, Cremes und Flüssigkeiten sowie verschreibungspflichtige Arzneimittel.
Marksans Pharma Limited's Grundlagenzusammenfassung
| MARKSANS grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹145.40b |
| Gewinn(TTM) | ₹5.17b |
| Umsatz(TTM) | ₹31.72b |
Ist MARKSANS zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| MARKSANS Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹31.72b |
| Kosten der Einnahmen | ₹14.20b |
| Bruttogewinn | ₹17.52b |
| Sonstige Ausgaben | ₹12.35b |
| Gewinn | ₹5.17b |
Zuletzt gemeldete Gewinne
Jun 30, 2026
Datum des nächsten Gewinnberichts
k.A.
| Gewinn per Aktie (EPS) | 11.40 |
| Bruttomarge | 55.25% |
| Nettogewinnspanne | 16.29% |
| Schulden/Eigenkapital-Verhältnis | 11.2% |
Wie hat sich MARKSANS auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt MARKSANS eine zuverlässige Dividende?
Siehe MARKSANS Dividendenhistorie und Benchmarks| Marksans Pharma Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Aug 20 2026 |
| Datum der Dividendenzahlung | Sep 26 2026 |
| Tage bis Ex-Dividende | 1 day |
| Tage bis zum Datum der Dividendenzahlung | 36 days |
Zahlt MARKSANS eine zuverlässige Dividende?
Siehe MARKSANS Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/20 00:34 |
| Aktienkurs zum Tagesende | 2026/08/20 00:00 |
| Gewinne | 2026/06/30 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Marksans Pharma Limited wird von 4 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Ranjit Kapadia | Centrum Broking Limited |
| Maitri Sheth | Choice Equity Broking Private Limited |
| Nitin Agarwal | DAM Capital Advisors |